Reckitt Benckiser Group (LSE:RKT) has spent much of the last 18 months reshaping itself for a simpler, more focused future. The Slough-based FTSE 100 consumer health and hygiene group owns global brands including Dettol, Nurofen, Strepsils, Durex, Finish and Vanish, plus the Mead Johnson infant nutrition Business behind Enfamil. After agreeing in 2025 to sell its Essential Home portfolio to Advent International for $4.8 billion, completing the deal at the end of 2025 and returning Capital to shareholders in 2026, Reckitt is now firmly in the spotlight of UK investors looking for defensive growth and Dividend income.

This article reviews Reckitt’s recent performance, share price, dividends and the sector trends shaping the stock. It is a journalist’s overview of publicly available information and is not Investment advice.

Key takeaways

  • Core Reckitt net Revenue grew 5.2% in FY 2025, ahead of upgraded guidance of above 4%, according to the company’s full-year results.
  • Group net revenue increased 5% in FY 2025, including Mead Johnson Nutrition growth of 3.8%.
  • Mead Johnson adjusted operating profit grew 14.0% at constant FX to £433m in 2025, with gross Margin rising to 61.1%.
  • Reckitt completed the sale of Essential Home to Advent International on 31 December 2025 for $4.8 billion, retaining a 30% stake.
  • An anticipated Special Dividend of around $2.2 billion was set to return excess capital to shareholders following the disposal.
  • On 18 May 2026, Reckitt shares were trading around 4,613p, with market data sources reporting a prospective Yield of about 5%.

Why investors are watching this FTSE 100 stock

Reckitt is undergoing one of the most significant portfolio resets in the consumer staples sector. Under its current strategy, the group is focusing on what it calls “Powerbrands”: market-leading consumer health and hygiene names such as Dettol, Mucinex, Strepsils and Nurofen. The disposal of Essential Home, which housed brands including Air Wick, Cillit Bang, Calgon and Mortein, is intended to leave a smaller, faster-growing, higher-margin business with a clearer narrative.

UK investors are watching whether this simplification can translate into better organic growth, stronger free Cash Flow conversion and a re-rating of the shares. The stock has been a notable underperformer compared with its history as a high-quality consumer staples name, and the special dividend tied to the Essential Home sale has reinforced the importance of capital returns in the investment case.

Reckitt also retains Mead Johnson Nutrition, the global infant formula business. Following the Mount Vernon tornado disruption in 2024, Mead Johnson trading has recovered strongly, with FY 2025 results showing improved revenue, margin and operating profit. Investors are watching whether the company eventually pursues a separate strategic path for Mead Johnson over time.

Recent share price performance

Where the shares sit in May 2026

Reckitt shares were trading at around 4,613p on 18 May 2026, with the company’s Market Capitalisation reported at approximately $40.7 billion. According to one analyst commentary, the shares were down around 21% year-to-date in 2026 by late April, leaving the prospective Dividend Yield at around 5%.

Drivers of the 2026 move

The price action reflects a combination of headwinds and self-help. Investors have weighed the strategic clarity created by the Essential Home disposal and the planned $2.2 billion special dividend against ongoing concerns about consumer Demand, currency moves and competitive intensity. According to company commentary, FY 2025 core Reckitt revenue growth of 5.2% beat upgraded guidance.

Longer-term context

Reckitt’s share price history is closely tied to the trajectory of Mead Johnson, the legacy IFCN business acquired in 2017 for around $17 billion. The 2024 Mount Vernon tornado disrupted US production, and earlier US litigation linked to specialised infant formula products has been a recurring source of share-price Volatility. The current strategy seeks to put more of the focus on Powerbrand growth, supported by margin and cash flow improvements.

Business performance and Earnings

Reckitt reported FY 2025 core Reckitt net revenue growth of 5.2%, ahead of an upgraded guidance of above 4%. Group net revenue grew 5%, including Mead Johnson Nutrition growth of 3.8%, driven by premiumisation and speciality Brand strength. According to the company, North America delivered mid-single-digit growth for the year, with recovery in Market Share and Nutramigen driving price/mix benefit.

Mead Johnson Nutrition adjusted operating profit grew 14.0% at constant FX to £433m in 2025, including a net benefit of £25m of insurance proceeds related to the Mount Vernon tornado. Mead Johnson gross margin increased to 61.1%, up from 59.5% in FY 2024, on favourable production volumes against a lower prior year. The company indicated that Mead Johnson is trading well and is expected to have another good year in 2026.

The H1 fiscal 2026 trajectory will be a key test of whether the simpler Powerbrand-focused portfolio can deliver consistent growth. According to commentary around the Q3 2025 trading update and subsequent FY 2025 results, the company has been pushing innovation in core categories, including Nurofen and Strepsils variants, while increasing brand investment in Mucinex and Lysol.

Dividends and Shareholder returns

Reckitt remains a notable dividend payer in the FTSE 100. The last reported Dividend per share was 244.79p as of early May 2026, according to one data source. Market data sources also report a prospective yield of around 5%, although other forward-yield calculations vary depending on assumptions about the special dividend and timing.

The biggest near-term shareholder return event is the planned $2.2 billion special dividend following completion of the Essential Home disposal at the end of 2025. Combined with the ordinary dividend and ongoing share repurchases, this represents a significant capital return cycle for shareholders. According to the company, the broader strategy is to balance reinvestment in brands with consistent capital returns.

Future dividend growth will depend on the pace of organic revenue growth, margin development and cash conversion. UK investors should also bear in mind that special dividends are typically one-off events and should not be assumed to recur in future years.

Valuation and market position

Reckitt is one of the larger consumer health and hygiene businesses in the FTSE 100, alongside Unilever (which has a broader portfolio across food, beauty, home and personal care) and Haleon (a more specialised consumer healthcare group). Reckitt’s positioning, after the Essential Home disposal, sits closer to a focused health and hygiene group with a strong infant nutrition Franchise.

Valuation multiples for Reckitt have come down significantly from the highs of the late 2010s, reflecting slower growth, US litigation noise and broader consumer staples derating. The company’s relatively high dividend yield versus history is partly a function of the share price decline and partly a reflection of management’s commitment to returning capital. According to market commentary, the question for investors is whether the simpler portfolio can drive better organic growth and free cash flow over the medium term.

Compared with global consumer health peers, Reckitt offers a different mix: significant exposure to Mead Johnson, a leading global position in hygiene through Dettol, Lysol and Finish, and a portfolio of OTC brands. The retained 30% stake in Essential Home also provides some optionality.

Sector trends shaping Reckitt

Several long-term themes continue to support the consumer health sector. Ageing populations are using more OTC products, hygiene awareness has remained elevated since the Pandemic and emerging market consumers are upgrading their health and wellness spend. Reckitt’s mix of Powerbrands is positioned across many of these themes, with Dettol particularly well known across multiple emerging markets.

Within infant nutrition, Mead Johnson operates in a structurally complex category. Birth rates in some major markets are slowing, but premiumisation and demand for speciality formulas such as Nutramigen for cows’ milk allergy support continued mix improvement. According to Reckitt’s 2025 disclosures, the US business has returned to more normalised trading following the 2024 tornado disruption.

Competitive intensity, retailer power and the rise of private label remain ongoing pressures across consumer health and hygiene. Innovation pipelines, Marketing investment and Supply chain resilience are key competitive battlegrounds. Currency movements, regulatory changes in markets like China and shifting consumer behaviour also affect the outlook.

Risks to watch

Litigation and Regulatory Risk associated with Mead Johnson’s US infant formula business has been a recurring feature of the Reckitt story. While the company has worked through significant phases of this issue, ongoing or new claims could continue to affect sentiment. Investors are watching how the legal landscape evolves and how it interacts with broader US product Liability trends.

Other risks include the execution of the Powerbrands strategy, the performance of retained brands in OTC health and hygiene, currency translation effects on a multinational business, and competitive pressures from large multinationals and local challengers. According to the company, FY 2025 results were ahead of guidance, but consumer markets remain volatile and softer demand conditions in some categories could affect future growth.

Capital allocation is another area to watch. Following the Essential Home sale and the planned special dividend, investors are looking at how Reckitt allocates remaining capital between organic investment, ongoing Buybacks, the ordinary dividend, deleveraging and any potential portfolio moves involving Mead Johnson. As always, future outcomes are uncertain.